PERFORMANCE · Injectable
Ipamorelin.
Clean GH secretagogue — no cortisol spike
How it works
Class & mechanism.
Class
Growth Hormone Releasing Peptide (GHRP)
Mechanism
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that acts as a highly selective agonist of the growth hormone secretagogue receptor 1a (GHS-R1a) — the same receptor activated by the hunger hormone ghrelin. Upon binding, it triggers a rapid, acute pulse of GH release from anterior pituitary somatotrophs via intracellular calcium mobilisation and inhibition of somatostatin tone. Critically, its receptor selectivity is so narrow that it does not significantly elevate cortisol, ACTH, prolactin, or aldosterone — the off-target hormonal activations that limit clinical utility of older GHRPs like GHRP-2 and GHRP-6.
Did you know
Ipamorelin was developed by Novo Nordisk — the same company behind Ozempic — and completed multiple Phase I and II human clinical trials, making it one of the most rigorously characterised research peptides in existence despite never reaching commercial approval.
Benefits
What it does.
Selective GH stimulation with no meaningful cortisol or stress-hormone spike
Increased lean muscle mass and reduction in abdominal body fat
Improved sleep quality and cellular repair through elevated IGF-1
Enhanced bone mineral density and collagen synthesis over prolonged use
The science
Peer-reviewed findings.
Research supporting this compound's mechanisms and safety profile.
In the foundational characterisation study, ipamorelin was demonstrated to stimulate GH release exclusively through a GHRP-like receptor pathway — not the GHRH receptor — and unlike GHRP-6 and hexarelin produced no statistically significant rise in ACTH or cortisol in swine models. The authors concluded it was 'the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH.'
SOURCE · Raun K et al., Eur J Endocrinol, 1998 Nov;139(5):552–61 (PMID 9849822)
Pharmacokinetic-pharmacodynamic modelling in healthy human volunteers confirmed rapid GH peak (within ~40 minutes of administration) and a plasma half-life of approximately 2 hours, supporting once- or twice-daily subcutaneous dosing as sufficient to generate meaningful pulsatile GH events.
SOURCE · Gobburu JV et al., Pharm Res, 1999 Sep;16(9):1412–6 (PMID 10496658)
Protocol
How to use it.
Dosing
200–300 mcg per injection, subcutaneous, once or twice daily. Evening administration before sleep is preferred to synchronise with the body's endogenous nocturnal GH surge. Frequently stacked with a GHRH analogue (CJC-1295 No DAC or Tesamorelin) for synergistic pituitary stimulation via complementary receptor pathways.
Cycle
Cycles of 8–12 weeks are standard, typically followed by a 4-week wash-out period. Initial improvements in sleep quality and energy are often reported within 2–4 weeks; body composition changes — increased lean mass and reduced fat — typically become measurable after 3–6 months of consistent use with appropriate training and diet.
Contraindications
When to skip it.
Avoid in active cancer or high cancer risk (IGF-1 elevation). Use with caution in insulin-resistant or diabetic individuals. Contraindicated in pregnancy. Common side effects are mild: transient headache, flushing, or light dizziness at injection. Unlike GHRP-6, appetite stimulation is minimal at standard research doses. Medical supervision and periodic IGF-1 monitoring are advised.
Always cleared with your concierge before protocol start.
Pricing
What it costs.
Indicative range for Ipamorelin, sourced from vetted US and EU dispensing suppliers. Concierge confirms the exact figure once your match is locked.
Indicative range (USD)
Sourced through vetted dispensing partners in the United States and European Union. Concierge confirms the exact figure once your match is locked.
- 0199% purity verified, third-party tested
- 02Includes vial and reconstitution guidance
- 03Concierge supplier match included with every protocol
See Ipamorelin pricing — and your supplier match.
Pricing is unlocked once we know who you are. Take the 3-minute quiz and we'll match you to a US or EU dispensary based on your location and protocol fit.
- Live USD price range
- US & EU supplier shortlist
- Concierge sign-off on dosing
Indicative price range: $90–$134 USD